Valuation : AbbVie Inc.

Market Cap 453B 390B 367B 335B 626B 42,860B 628B 4,346B 1,680B 21,949B 1,702B 1,665B 69,913B P/E 2026 *
32.8x
P/E 2027 * 24.4x
Enterprise Value 514B 442B 415B 379B 709B 48,581B 712B 4,926B 1,904B 24,878B 1,929B 1,887B 79,245B EV / Sales 2026 *
7.6x
EV / Sales 2027 * 6.87x
Free-Float
95.71%
Yield 2026 *
2.67%
Yield 2027 * 2.81%
04:15pm BofA Securities Adjusts Price Target on AbbVie to $282 From $276 MT
09-03 AbbVie Announces Positive Topline Results From The Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma CI
09-03 AbbVie Inc. completed the acquisition of Apogee Therapeutics, Inc. from Fairmount Healthcare Fund II L.P managed by Fairmount Funds Management LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P managed by Venrock Management, LLC and other shareholders. CI
09-03 AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints MT
09-03 AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study DJ
09-03 AbbVie's blood cancer therapy lowers disease progression, death risk in trial RE
09-03 AbbVie's blood cancer drug meets late-stage trial goals RE
09-03 AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics MT
09-01 Global pharma companies that have publicly announced Trump drug pricing agreements RE
09-01 AbbVie Inc Receives Determination From Food And Drug Administration Regarding NAMENDA (Memantine Hydrochloride) Tablets 5 Mg And 10 Mg CI
08-27 AbbVie Seeks EU Approval for Subcutaneous Skyrizi Induction in Crohn's Disease MT
08-27 AbbVie Seeks European Regulatory Nod to Use Skyrizi as Subcutaneous Induction for Crohn's Disease Treatment MT
08-27 AbbVie Submits Regulatory Application To EMA For SKYRIZI (Risankizumab) Subcutaneous Induction For Adults With Moderately To Severely Active Crohn's Disease CI
1 day-1.58%
1 week-3.21%
Current month-1.87%
1 month+1.48%
3 months+12.81%
6 months+10.63%
Current year+10.13%
1 week 250.54
Extreme 250.54
264.25
1 month 244.03
Extreme 244.03
266.96
Current year 190.75
Extreme 190.75
267.47
1 year 190.75
Extreme 190.75
267.47
3 years 135.85
Extreme 135.85
267.47
5 years 105.56
Extreme 105.56
267.47
10 years 55.06
Extreme 55.0623
267.47
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap. Importance
14/08/26 Exercice

Executive/Senior Manager

98,130 0.0056%
30/06/26 Free

Director

62 0.0000%
30/06/26 Free

Director

134 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%-3.21%+19.95%+68.86% 453B
-1.47%-2.57%+53.01%+92.72% 1,024B
-2.33%-0.22%+51.90%+68.53% 663B
-0.47%+1.21%+30.21%+37.01% 349B
-10.47%-14.22%+9.79%+27.49% 295B
-0.96%-0.38%-0.45%+9.87% 253B
-8.96%-9.50%+41.51%+52.83% 236B
-2.04%-0.34%-15.58%-56.77% 206B
-3.01%-2.21%+26.51%+92.89% 187B
-1.81%-1.87%+14.11%-18.20% 162B
Average -3.31%+0.97%+23.10%+37.52% 382.95B
Weighted average by Cap. -2.78%+0.43%+32.63%+54.95%

Financials

2026 *2027 *
Net sales 67.58B 58.12B 54.67B 49.9B 93.33B 6,392B 93.63B 648B 251B 3,273B 254B 248B 10,426B 73.52B 63.23B 59.47B 54.28B 102B 6,953B 102B 705B 273B 3,561B 276B 270B 11,342B
Net income 13.86B 11.92B 11.21B 10.24B 19.14B 1,311B 19.2B 133B 51.39B 671B 52.06B 50.92B 2,138B 18.91B 16.27B 15.3B 13.97B 26.12B 1,789B 26.2B 181B 70.12B 916B 71.03B 69.48B 2,918B
Net Debt 60.49B 52.02B 48.93B 44.66B 83.53B 5,721B 83.8B 580B 224B 2,930B 227B 222B 9,332B 51.66B 44.43B 41.79B 38.15B 71.34B 4,886B 71.57B 495B 192B 2,502B 194B 190B 7,970B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
08/09/26 $252.08 -1.71% 1,162,513
04/09/26 $256.46 -1.44% 4,729,800
03/09/26 $260.21 -0.58% 2,878,739
02/09/26 $261.72 +0.67% 4,225,524
01/09/26 $259.99 +1.39% 3,866,739
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
256.46USD
Average target price
276.79USD
Spread / Average Target
+7.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!